Is it safe to use smoking cessation therapeutics during pregnancy?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Abingdon, Oxford : Taylor & Francis
      Original Publication: London : Ashley Publications, c2002-
    • Subject Terms:
      Benzazepines/*adverse effects ; Bupropion/*adverse effects ; Quinoxalines/*adverse effects; Animals ; Benzazepines/pharmacology ; Benzazepines/therapeutic use ; Bupropion/pharmacology ; Bupropion/therapeutic use ; Female ; Humans ; Pregnancy ; Quinoxalines/pharmacology ; Quinoxalines/therapeutic use ; Smoking/therapy ; Smoking Cessation/methods ; Varenicline
    • Abstract:
      Introduction: Worldwide, 10 to 35% of pregnant women smoke. It is clear that smoking cessation has positive impacts for both the mother and child, yet many women are still unable to quit due to the addictive properties of nicotine. There are limited data surrounding their safety and efficacy in pregnancy.
      Areas Covered: This review highlights evidence from clinical studies and animal experiments regarding the effects of smoking cessation therapeutics on pregnancy, neonatal and long-term postnatal outcomes.
      Expert Opinion: There are insufficient data at this time to recommend the use of varenicline and/or bupropion for smoking cessation during pregnancy. In addition, the efficacy and safety of nicotine replacement therapy use for smoking cessation in pregnant women has not been clearly demonstrated. Until further studies are completed, there will continue to be considerable uncertainty regarding the use of these drugs in pregnancy despite the well-documented benefits of smoking cessation.
    • Grant Information:
      Canada Canadian Institutes of Health Research
    • Contributed Indexing:
      Keywords: bupropion; e-cigarettes; nicotine replacement therapy; varenicline
    • Accession Number:
      0 (Benzazepines)
      0 (Quinoxalines)
      01ZG3TPX31 (Bupropion)
      W6HS99O8ZO (Varenicline)
    • Publication Date:
      Date Created: 20141022 Date Completed: 20150707 Latest Revision: 20151119
    • Publication Date:
      20231215
    • Accession Number:
      10.1517/14740338.2014.973846
    • Accession Number:
      25330815